Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1.

Publication

Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1.

Journal Paper/Review - Mar 2, 2023

Balakrishna Suraj, Loosli Tom, Zaheri Maryam, Frischknecht Paul, Huber Michael, Kusejko Katharina, Yerly Sabine, Leuzinger Karoline, Perreau Matthieu, Ramette Alban Nicolas, Wymant Chris, Fraser Christophe, Kellam Paul, Gall Astrid, Hirsch Hans H., Stoeckle Marcel, Rauch Andri, Cavassini Matthias, Bernasconi Enos, Notter Julia, Calmy Alexandra, Günthard Huldyrich F, Metzner Karin J, Kouyos Roger D

Citation

Balakrishna S, Loosli T, Zaheri M, Frischknecht P, Huber M, Kusejko K, Yerly S, Leuzinger K, Perreau M, Ramette A, Wymant C, Fraser C, Kellam P, Gall A, Hirsch H, Stoeckle M, Rauch A, Cavassini M, Bernasconi E, Notter J, Calmy A, Günthard H, Metzner K, Kouyos R. Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1. J Antimicrob Chemother 2023; 78:656-664.

Type

Journal Paper/Review (English)

Journal

J Antimicrob Chemother 2023; 78

Publication Date

Mar 2, 2023

Issn Electronic

1460-2091

Pages

656-664

Brief description/objective

Next-generation sequencing (NGS) is gradually replacing Sanger sequencing (SS) as the primary method for HIV genotypic resistance testing. However, there are limited systematic data on comparability of these methods in a clinical setting for the presence of low-abundance drug resistance mutations (DRMs) and their dependency on the variant-calling thresholds.